	US 12,006,319 B2
	Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
Suzanne Buttar, Cambridge (GB); Mateusz Pitak, Cambridge (GB); Adam Ross Patterson, Cambridge (GB); Samuel Alexander Stratford, Cambridge (GB); Ioana Sovago, Cambridge (GB); Jun Xu, Cambridge (GB); Peng Zhou, Cambridge (GB); Haojuan Wei, Changzhou (CN); and Kuangchu Dai, Changzhou (CN)
Assigned to Cardurion Pharmaceuticals, Inc., Burlington, MA (US)
Filed by Cardurion Pharmaceuticals, Inc., Burlington, MA (US)
Filed on Dec. 2, 2020, as Appl. No. 17/110,000.
Application 17/110,000 is a continuation of application No. PCT/US2019/033835, filed on May 23, 2019.
Claims priority of provisional application 62/788,323, filed on Jan. 4, 2019.
Claims priority of provisional application 62/676,381, filed on May 25, 2018.
Prior Publication US 2021/0107911 A1, Apr. 15, 2021
Int. Cl. C07D 487/04 (2006.01); A61K 31/4985 (2006.01)

CPC C07D 487/04 (2013.01) [C07B 2200/13 (2013.01)]

20 Claims

1. A monohydrate crystalline form of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one